Literature DB >> 10906126

Isolation and characterization of two novel phosphodiesterase PDE11A variants showing unique structure and tissue-specific expression.

K Yuasa1, J Kotera, K Fujishige, H Michibata, T Sasaki, K Omori.   

Abstract

cDNAs encoding a novel phosphodiesterase, phosphodiesterase 11A (PDE11A), were isolated by a combination of reverse transcriptase-polymerase chain reaction using degenerate oligonucleotide primers and rapid amplification of cDNA ends. Their catalytic domain was identical to that of PDE11A1 (490 amino acids) reported during the course of this study. However, the cDNAs we isolated had N termini distinct from PDE11A1, indicating two novel N-terminal variants of PDE11A. PDE11A3 cDNA encoded a 684-amino acid protein including one complete and one incomplete GAF domain in the N-terminal region. PDE11A4 was composed of 934 amino acids including two complete GAF domains and shared 630 C-terminal amino acids with PDE11A3 but had a distinct N terminus containing the putative phosphorylation sites for cAMP- and cGMP-dependent protein kinases. PDE11A3 transcripts were specifically expressed in testis, whereas PDE11A4 transcripts were particularly abundant in prostate. Recombinant PDE11A4 expressed in COS-7 cells hydrolyzed cAMP and cGMP with K(m) values of 3.0 and 1.4 microm, respectively, and the V(max) value with cAMP was almost twice that with cGMP. Although PDE11A3 showed the same K(m) values as PDE11A4, the relative V(max) values of PDE11A3 were approximately one-sixth of those of PDE11A4. PDE11A4, but not PDE11A3, was phosphorylated by both cAMP- and cGMP-dependent protein kinases in vitro. Thus, the PDE11A gene undergoes tissue-specific alternative splicing that generates structurally and functionally distinct gene products.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10906126     DOI: 10.1074/jbc.M003041200

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  32 in total

Review 1.  Cyclic nucleotide phosphodiesterase (PDE) isozymes as targets of the intracellular signalling network: benefits of PDE inhibitors in various diseases and perspectives for future therapeutic developments.

Authors:  Thérèse Keravis; Claire Lugnier
Journal:  Br J Pharmacol       Date:  2012-03       Impact factor: 8.739

Review 2.  Phosphodiesterase function and endocrine cells: links to human disease and roles in tumor development and treatment.

Authors:  Isaac Levy; Anelia Horvath; Monalisa Azevedo; Rodrigo Bertollo de Alexandre; Constantine A Stratakis
Journal:  Curr Opin Pharmacol       Date:  2011-10-31       Impact factor: 5.547

3.  Activation of PDE10 and PDE11 phosphodiesterases.

Authors:  Ronald Jäger; Corina Russwurm; Frank Schwede; Hans-Gottfried Genieser; Doris Koesling; Michael Russwurm
Journal:  J Biol Chem       Date:  2011-11-21       Impact factor: 5.157

Review 4.  Cyclic nucleotide phosphodiesterases as targets for treatment of haematological malignancies.

Authors:  Adam Lerner; Paul M Epstein
Journal:  Biochem J       Date:  2006-01-01       Impact factor: 3.857

5.  Promoter methylation of candidate genes associated with familial testicular cancer.

Authors:  Lisa Mirabello; Christian P Kratz; Sharon A Savage; Mark H Greene
Journal:  Int J Mol Epidemiol Genet       Date:  2012-08-31

Review 6.  Phosphodiesterases and adrenal Cushing in mice and humans.

Authors:  E Szarek; C A Stratakis
Journal:  Horm Metab Res       Date:  2014-09-18       Impact factor: 2.936

Review 7.  A Role for Phosphodiesterase 11A (PDE11A) in the Formation of Social Memories and the Stabilization of Mood.

Authors:  Michy P Kelly
Journal:  Adv Neurobiol       Date:  2017

Review 8.  RNA splicing in regulation of nitric oxide receptor soluble guanylyl cyclase.

Authors:  Iraida G Sharina; Gilbert J Cote; Emil Martin; Marie-Francoise Doursout; Ferid Murad
Journal:  Nitric Oxide       Date:  2011-08-16       Impact factor: 4.427

9.  Phosphodiesterase 10A Is Tethered to a Synaptic Signaling Complex in Striatum.

Authors:  Corina Russwurm; Doris Koesling; Michael Russwurm
Journal:  J Biol Chem       Date:  2015-03-11       Impact factor: 5.157

Review 10.  [The basics of phosphodiesterase type 5 (PDE5) inhibition in urology].

Authors:  A J Becker; S Uckert; C G Stief
Journal:  Urologe A       Date:  2008-12       Impact factor: 0.639

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.